中信里昂:维持康方生物(09926.HK)目标价177港元 评级“跑赢大市“

智通财经
Sep 08
【中信里昂:维持康方生物(09926.HK)目标价177港元 评级“跑赢大市“】智通财经APP获悉,中信里昂发布研报称,维持康方生物(09926.HK)目标价177港元以及"跑赢大市"评级。9月7日,康方生物及其合作伙伴Summit Therapeutics在2025年世界肺癌大会(WCLC)上公布 ivonescimab 用于治疗二线估计肾丝球过滤率(EGFR)+非小细胞肺癌(NSCLC)的全球III期Harmoni研究数据,该数据呈逐步积极的趋势。 总生存期(OS)风险趋势从0.79改善至0.78,北美和亚洲亚组报告的风险比分别为0.7和0.76,表现良好。值得关注的下一个催化剂是2025年欧洲肿瘤内科学会(ESMO)上发表的Harmoni-6与替雷利珠单抗(tislelizumab)的第二期III期头对头临床试验结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10